JP2018533375A5 - - Google Patents

Download PDF

Info

Publication number
JP2018533375A5
JP2018533375A5 JP2018542995A JP2018542995A JP2018533375A5 JP 2018533375 A5 JP2018533375 A5 JP 2018533375A5 JP 2018542995 A JP2018542995 A JP 2018542995A JP 2018542995 A JP2018542995 A JP 2018542995A JP 2018533375 A5 JP2018533375 A5 JP 2018533375A5
Authority
JP
Japan
Prior art keywords
nucleotide sequence
cas9 molecule
targeting domain
gene
hsv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018542995A
Other languages
English (en)
Japanese (ja)
Other versions
JP7408284B2 (ja
JP2018533375A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/059502 external-priority patent/WO2017075475A1/en
Publication of JP2018533375A publication Critical patent/JP2018533375A/ja
Publication of JP2018533375A5 publication Critical patent/JP2018533375A5/ja
Priority to JP2022007688A priority Critical patent/JP2022068156A/ja
Priority to JP2023206552A priority patent/JP2024055867A/ja
Application granted granted Critical
Publication of JP7408284B2 publication Critical patent/JP7408284B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018542995A 2015-10-30 2016-10-28 単純ヘルペスウイルスを治療するためのcrispr/cas関連方法及び組成物 Active JP7408284B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022007688A JP2022068156A (ja) 2015-10-30 2022-01-21 単純ヘルペスウイルスを治療するためのcrispr/cas関連方法及び組成物
JP2023206552A JP2024055867A (ja) 2015-10-30 2023-12-07 単純ヘルペスウイルスを治療するためのcrispr/cas関連方法及び組成物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562249071P 2015-10-30 2015-10-30
US201562249159P 2015-10-30 2015-10-30
US62/249,159 2015-10-30
US62/249,071 2015-10-30
PCT/US2016/059502 WO2017075475A1 (en) 2015-10-30 2016-10-28 Crispr/cas-related methods and compositions for treating herpes simplex virus

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022007688A Division JP2022068156A (ja) 2015-10-30 2022-01-21 単純ヘルペスウイルスを治療するためのcrispr/cas関連方法及び組成物

Publications (3)

Publication Number Publication Date
JP2018533375A JP2018533375A (ja) 2018-11-15
JP2018533375A5 true JP2018533375A5 (enExample) 2019-12-05
JP7408284B2 JP7408284B2 (ja) 2024-01-05

Family

ID=57321423

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018542995A Active JP7408284B2 (ja) 2015-10-30 2016-10-28 単純ヘルペスウイルスを治療するためのcrispr/cas関連方法及び組成物
JP2022007688A Withdrawn JP2022068156A (ja) 2015-10-30 2022-01-21 単純ヘルペスウイルスを治療するためのcrispr/cas関連方法及び組成物
JP2023206552A Pending JP2024055867A (ja) 2015-10-30 2023-12-07 単純ヘルペスウイルスを治療するためのcrispr/cas関連方法及び組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022007688A Withdrawn JP2022068156A (ja) 2015-10-30 2022-01-21 単純ヘルペスウイルスを治療するためのcrispr/cas関連方法及び組成物
JP2023206552A Pending JP2024055867A (ja) 2015-10-30 2023-12-07 単純ヘルペスウイルスを治療するためのcrispr/cas関連方法及び組成物

Country Status (7)

Country Link
US (2) US11001844B2 (enExample)
EP (1) EP3368670A1 (enExample)
JP (3) JP7408284B2 (enExample)
CN (2) CN115491373A (enExample)
AU (2) AU2016343991B2 (enExample)
CA (1) CA3001711A1 (enExample)
WO (1) WO2017075475A1 (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10323236B2 (en) 2011-07-22 2019-06-18 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
US11053481B2 (en) 2013-12-12 2021-07-06 President And Fellows Of Harvard College Fusions of Cas9 domains and nucleic acid-editing domains
CA2935960C (en) 2014-01-08 2023-01-10 Bart Lipkens Acoustophoresis device with dual acoustophoretic chamber
EP4079847A1 (en) 2014-07-30 2022-10-26 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
MA41349A (fr) * 2015-01-14 2017-11-21 Univ Temple Éradication de l'herpès simplex de type i et d'autres virus de l'herpès associés guidée par arn
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
IL294014B2 (en) 2015-10-23 2024-07-01 Harvard College Nucleobase editors and uses thereof
US11299751B2 (en) 2016-04-29 2022-04-12 Voyager Therapeutics, Inc. Compositions for the treatment of disease
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
WO2018027078A1 (en) 2016-08-03 2018-02-08 President And Fellows Of Harard College Adenosine nucleobase editors and uses thereof
US11661590B2 (en) 2016-08-09 2023-05-30 President And Fellows Of Harvard College Programmable CAS9-recombinase fusion proteins and uses thereof
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
SG11201903089RA (en) 2016-10-14 2019-05-30 Harvard College Aav delivery of nucleobase editors
WO2018081504A1 (en) * 2016-10-28 2018-05-03 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating herpes simplex virus
US10745677B2 (en) 2016-12-23 2020-08-18 President And Fellows Of Harvard College Editing of CCR5 receptor gene to protect against HIV infection
EP3592853A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Suppression of pain by gene editing
EP3592381A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Cancer vaccine
CN110914310A (zh) 2017-03-10 2020-03-24 哈佛大学的校长及成员们 胞嘧啶至鸟嘌呤碱基编辑器
GB2575930A (en) 2017-03-23 2020-01-29 Harvard College Nucleobase editors comprising nucleic acid programmable DNA binding proteins
WO2018209320A1 (en) 2017-05-12 2018-11-15 President And Fellows Of Harvard College Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
US11732274B2 (en) 2017-07-28 2023-08-22 President And Fellows Of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
EP3676376B1 (en) 2017-08-30 2025-01-15 President and Fellows of Harvard College High efficiency base editors comprising gam
WO2019079347A1 (en) 2017-10-16 2019-04-25 The Broad Institute, Inc. USES OF BASIC EDITORS ADENOSINE
KR20220066413A (ko) 2017-12-14 2022-05-24 프로디자인 소닉스, 인크. 음향 트랜스듀서 구동기 및 제어기
WO2019118949A1 (en) 2017-12-15 2019-06-20 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
CA3089843A1 (en) * 2018-01-30 2019-08-08 Editas Medicine, Inc. Systems and methods for modulating chromosomal rearrangements
EP3746556A1 (en) * 2018-02-01 2020-12-09 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating herpes simplex virus (hsv) related keratitis
AU2019236210B2 (en) 2018-03-14 2025-07-03 Arbor Biotechnologies, Inc. Novel CRISPR DNA targeting enzymes and systems
WO2019226953A1 (en) 2018-05-23 2019-11-28 The Broad Institute, Inc. Base editors and uses thereof
WO2020055941A1 (en) * 2018-09-13 2020-03-19 Excision Biotherapeutics, Inc. Compositions and methods for excision with single grna
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
EP3918071A1 (en) * 2019-02-01 2021-12-08 Editas Medicine, Inc. Crispr/cas-related methods and compositions targeting virus genomes
DE112020001342T5 (de) 2019-03-19 2022-01-13 President and Fellows of Harvard College Verfahren und Zusammensetzungen zum Editing von Nukleotidsequenzen
WO2020214842A1 (en) 2019-04-17 2020-10-22 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
WO2021072328A1 (en) 2019-10-10 2021-04-15 The Broad Institute, Inc. Methods and compositions for prime editing rna
EP4081241A4 (en) 2019-12-24 2024-05-01 Juvena Therapeutics, Inc. REGENERATIVE POLYPEPTIDES AND THEIR USES
GB2614813B (en) 2020-05-08 2025-05-07 Harvard College Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
EP4179085A1 (en) * 2020-07-07 2023-05-17 Oriengene Biotechnology Ltd Guide rna for hsv-1 gene editing and method thereof
US20240271128A1 (en) * 2020-10-02 2024-08-15 Temple University - Of The Commonwealth System Of Higher Education Rna guided eradication of herpes simplex type i and other related human herpesviruses
WO2022170059A1 (en) 2021-02-05 2022-08-11 Christiana Care Health Services, Inc. Methods of and compositions for reducing gene expression and/or activity
CN117999278A (zh) 2021-06-21 2024-05-07 裘美娜治疗公司 再生性多肽及其用途
WO2024113302A1 (zh) * 2022-12-01 2024-06-06 深圳先进技术研究院 靶向HSV必需基因的gRNA、CRISPR/Cas基因编辑系统、递送系统及应用
CN116121271B (zh) * 2022-12-21 2025-05-09 四川农业大学 多杀性巴氏杆菌arcA基因及其应用
US12227748B1 (en) * 2024-04-25 2025-02-18 King Saud University Aptamers for binding to a membrane-based lipid

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9102126D0 (en) * 1991-01-31 1991-03-13 Smithkline Beecham Biolog Novel vaccine
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US5725493A (en) 1994-12-12 1998-03-10 Avery; Robert Logan Intravitreal medicine delivery
US6299895B1 (en) 1997-03-24 2001-10-09 Neurotech S.A. Device and method for treating ophthalmic diseases
US6416777B1 (en) 1999-10-21 2002-07-09 Alcon Universal Ltd. Ophthalmic drug delivery device
TR200201047T2 (tr) 1999-10-21 2002-07-22 Alcon, Inc. İlaç verme vasıtası.
US7074596B2 (en) 2002-03-25 2006-07-11 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synthesis and use of anti-reverse mRNA cap analogues
US7795419B2 (en) * 2004-05-26 2010-09-14 Rosetta Genomics Ltd. Viral and viral associated miRNAs and uses thereof
WO2008016473A2 (en) 2006-07-28 2008-02-07 Applera Corporation Dinucleotide mrna cap analogs
US8481506B2 (en) * 2006-12-05 2013-07-09 Rosetta Genomics, Ltd. Nucleic acids involved in viral infection
EA017740B1 (ru) 2007-06-19 2013-02-28 Борд Оф Сьюпервайзорз Оф Луизиана Стэйт Юниверсити Энд Эгрикалчурал Энд Мекэникал Колледж Синтез и применение антиинвертированных фосфоротиоатных аналогов кэп-структуры матричной phk
PL215513B1 (pl) 2008-06-06 2013-12-31 Univ Warszawski Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka
WO2013059475A1 (en) 2011-10-18 2013-04-25 Life Technologies Corporation Alkynyl-derivatized cap analogs, preparation and uses thereof
PL2931898T3 (pl) 2012-12-12 2016-09-30 Le Cong Projektowanie i optymalizacja systemów, sposoby i kompozycje do manipulacji sekwencją z domenami funkcjonalnymi
EP4372090A3 (en) 2013-11-07 2024-08-07 Editas Medicine, Inc. Crispr-related methods and compositions with governing grnas
EP3080261B1 (en) 2013-12-12 2019-05-22 The Broad Institute, Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for hbv and viral diseases and disorders
CA2940084A1 (en) * 2014-02-18 2015-08-27 Duke University Compositions for the inactivation of virus replication and methods of making and using the same
AU2015236128A1 (en) * 2014-03-25 2016-11-10 Editas Medicine Inc. CRISPR/CAS-related methods and compositions for treating HIV infection and AIDS
WO2015153791A1 (en) * 2014-04-01 2015-10-08 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating herpes simplex virus type 2 (hsv-2)
WO2015153789A1 (en) * 2014-04-01 2015-10-08 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating herpes simplex virus type 1 (hsv-1)
US10507232B2 (en) * 2014-04-02 2019-12-17 University Of Florida Research Foundation, Incorporated Materials and methods for the treatment of latent viral infection
KR20250102123A (ko) * 2014-04-18 2025-07-04 에디타스 메디신, 인코포레이티드 암 면역요법을 위한 crispr-cas-관련 방법, 조성물 및 구성성분
CA2954791C (en) 2014-07-14 2025-11-18 The Regents Of The Univ Of California Crispr/cas transcriptional modulation
US10071098B2 (en) * 2014-09-26 2018-09-11 Drexel University Compositions useful for treating herpes simplex labialis and/or herpes esophagitis, and methods using same
MA41349A (fr) * 2015-01-14 2017-11-21 Univ Temple Éradication de l'herpès simplex de type i et d'autres virus de l'herpès associés guidée par arn
WO2016161380A1 (en) 2015-04-01 2016-10-06 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating duchenne muscular dystrophy and becker muscular dystrophy
CA3046076A1 (en) * 2016-12-05 2018-06-14 Editas Medicine, Inc. Systems and methods for one-shot guide rna (ogrna) targeting of endogenous and source dna

Similar Documents

Publication Publication Date Title
JP2018533375A5 (enExample)
Peng et al. Engineering canker‐resistant plants through CRISPR/Cas9‐targeted editing of the susceptibility gene Cs LOB 1 promoter in citrus
US12431216B2 (en) Methods for identifying class 2 crispr-cas systems
Tsai et al. Complete genome sequence of the grouper iridovirus and comparison of genomic organization with those of other iridoviruses
Gentile et al. More evidence of collusion: a new prophage-mediated viral defense system encoded by mycobacteriophage Sbash
CN103088008B (zh) 胞苷脱氨酶及其编码基因和它们的应用
Suenaga et al. Engineering large viral DNA genomes using the CRISPR‐Cas9 system
EP3178935B1 (en) Genome editing using campylobacter jejuni crispr/cas system-derived rgen
JP2018534950A5 (enExample)
JP2016504026A5 (enExample)
JP2019524098A5 (enExample)
JP2019115348A5 (enExample)
Lee et al. Precise gene editing of chicken Na+/H+ exchange type 1 (chNHE1) confers resistance to avian leukosis virus subgroup J (ALV-J)
Mei et al. The C4 protein encoded by tomato leaf curl Yunnan virus reverses transcriptional gene silencing by interacting with NbDRM2 and impairing its DNA-binding ability
JP2016165307A5 (enExample)
JPH11253177A5 (enExample)
WO2015115903A1 (en) Site-specific dna break-induced genome editing using engineered nucleases
CN102703424B (zh) 一种重组工程介导的大肠杆菌基因组点突变的方法
Senčilo et al. A glimpse of the genomic diversity of haloarchaeal tailed viruses
Walter et al. Viral gene drive in herpesviruses
Ke et al. Divergent transcriptomic responses underlying the ranaviruses-amphibian interaction processes on interspecies infection of Chinese giant salamander
Guo et al. Highly efficient CRISPR/Cas9-mediated homologous recombination promotes the rapid generation of bacterial artificial chromosomes of pseudorabies virus
Chapon et al. Comprehensive mutagenesis of herpes simplex virus 1 genome identifies UL42 as an inhibitor of type I interferon induction
CN114144519B (zh) 单碱基置换蛋白以及包含其的组合物
US20180251787A1 (en) Crispr-cas10 systems and methods for phage genome editing